Precision BioSciences (NASDAQ:DTIL) CEO Michael Amoroso Sells 20,559 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 20,559 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total transaction of $78,946.56. Following the completion of the transaction, the chief executive officer owned 243,392 shares in the company, valued at $934,625.28. This represents a 7.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Thursday, January 22nd, Michael Amoroso sold 34,799 shares of Precision BioSciences stock. The shares were sold at an average price of $4.17, for a total value of $145,111.83.

Precision BioSciences Trading Down 3.7%

DTIL traded down $0.15 during midday trading on Friday, reaching $3.78. 38,118 shares of the company were exchanged, compared to its average volume of 219,939. The stock has a market capitalization of $86.45 million, a P/E ratio of -0.45 and a beta of 1.31. Precision BioSciences, Inc. has a one year low of $3.53 and a one year high of $8.82. The stock’s 50-day simple moving average is $4.14 and its 200 day simple moving average is $5.01. The company has a debt-to-equity ratio of 1.35, a quick ratio of 3.45 and a current ratio of 3.45.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors have recently bought and sold shares of the business. Empery Asset Management LP bought a new stake in shares of Precision BioSciences in the fourth quarter valued at about $9,130,000. Aberdeen Group plc acquired a new stake in Precision BioSciences in the 4th quarter worth about $8,897,000. Boothbay Fund Management LLC boosted its holdings in Precision BioSciences by 497.1% in the 4th quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock valued at $4,435,000 after purchasing an additional 887,515 shares during the period. Alyeska Investment Group L.P. bought a new stake in Precision BioSciences in the 4th quarter valued at about $3,320,000. Finally, Bleichroeder LP grew its position in shares of Precision BioSciences by 54.7% during the 4th quarter. Bleichroeder LP now owns 1,662,500 shares of the company’s stock worth $6,916,000 after purchasing an additional 587,500 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Precision BioSciences currently has a consensus rating of “Hold” and an average target price of $60.00.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.